

## Sun Pharma Advanced Research Company Limited

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara – 391 775. Tel. : +91-2667 666800

CIN : L73100GJ2006PLC047837. Website : www.sparc.life

### Statement of Unaudited Financial Results for the Quarter Ended June 30, 2023

₹ in Lakhs

Particulars	Quarter ended			Year ended
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	Unaudited	Audited	Unaudited	Audited
		(Refer Note 4)		
Revenue from operations	2,395	4,769	2,846	23,878
Other income	1,019	1,073	18	1,088
<b>Total income</b>	<b>3,414</b>	<b>5,842</b>	<b>2,864</b>	<b>24,966</b>
<b>Expenses</b>				
Cost of materials consumed	517	578	570	2,211
Employee benefits expense	3,112	2,990	2,550	10,699
Clinical trial expenses / products development expense (Refer Note 2)	3,698	5,829	3,307	14,947
Professional charges	4,135	3,387	3,164	13,195
Finance costs	26	21	163	763
Depreciation and amortisation expense	310	294	270	1,177
Other expenses	1,151	942	1,075	4,232
<b>Total expenses</b>	<b>12,949</b>	<b>14,041</b>	<b>11,099</b>	<b>47,224</b>
<b>Profit / (loss) before tax</b>	<b>(9,535)</b>	<b>(8,199)</b>	<b>(8,235)</b>	<b>(22,258)</b>
Tax expense	-	-	-	-
<b>Profit / (loss) for the period</b>	<b>(9,535)</b>	<b>(8,199)</b>	<b>(8,235)</b>	<b>(22,258)</b>
<b>Other comprehensive income (OCI)</b>				
Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)	34	8	42	135
<b>Total comprehensive profit / (loss) for the period</b>	<b>(9,501)</b>	<b>(8,191)</b>	<b>(8,193)</b>	<b>(22,123)</b>
Paid-up equity share capital (Face value ₹ 1 each)	3,245	3,245	2,719	3,245
Other equity				48,032
Basic and diluted earning / (loss) per equity share of ₹ 1 each	(2.94)	(2.55)	(3.03)	(7.82)
	Not annualised	Not annualised	Not annualised	Annualised
<i>See accompanying notes to the financial results</i>				

#### Notes :

- 1 The above unaudited financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on August 7, 2023 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- 2 During the previous quarter, the Company had paused the development of SCO-120 program due to changing clinical landscape. Pursuant to this, the Company had made provision for committed costs for this program estimated at ₹ 2,700 lakhs.
- 3 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 4 The figures of the previous quarter is the balancing figures between audited figures in respect of the full financial year up to March 31, 2023 and the unaudited published year-to-date figures up to December 31, 2022, being the date of the end of the third quarter of the previous financial years which was subjected to limited review.
- 5 Previous period figures have been regrouped / rearranged, wherever necessary.

For and on behalf of the Board

Dilip S. Shanghvi  
Chairman

Mumbai, August 7, 2023